These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18671770)

  • 1. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model.
    Sander B; Nizam A; Garrison LP; Postma MJ; Halloran ME; Longini IM
    Value Health; 2009; 12(2):226-33. PubMed ID: 18671770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
    Khazeni N; Hutton DW; Garber AM; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):840-53. PubMed ID: 20008760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies.
    Newall AT; Wood JG; Oudin N; MacIntyre CR
    Emerg Infect Dis; 2010 Feb; 16(2):224-30. PubMed ID: 20113551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigation of pandemic influenza: review of cost-effectiveness studies.
    Lugnér AK; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):547-58. PubMed ID: 19941432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts.
    Postma MJ; Milne G; Nelson EA; Pyenson B; Basili M; Coker R; Oxford J; Garrison LP;
    Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1431-9. PubMed ID: 21133667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic model for emergency use authorization of intravenous peramivir.
    Lee BY; Tai JH; Bailey RR; McGlone SM; Wiringa AE; Zimmer SM; Smith KJ; Zimmerman RK
    Am J Manag Care; 2011 Jan; 17(1):e1-9. PubMed ID: 21485418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health outcomes and costs of community mitigation strategies for an influenza pandemic in the United States.
    Perlroth DJ; Glass RJ; Davey VJ; Cannon D; Garber AM; Owens DK
    Clin Infect Dis; 2010 Jan; 50(2):165-74. PubMed ID: 20021259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral medications for pregnant women for pandemic and seasonal influenza: an economic computer model.
    Lee BY; Bailey RR; Wiringa AE; Assi TM; Beigi RH
    Obstet Gynecol; 2009 Nov; 114(5):971-980. PubMed ID: 20168096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories.
    Kelso JK; Halder N; Postma MJ; Milne GJ
    BMC Public Health; 2013 Mar; 13():211. PubMed ID: 23496898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost effectiveness of pandemic influenza interventions: a pandemic severity based analysis.
    Milne GJ; Halder N; Kelso JK
    PLoS One; 2013; 8(4):e61504. PubMed ID: 23585906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands.
    Keogh-Brown MR; Smith RD; Edmunds JW; Beutels P
    Eur J Health Econ; 2010 Dec; 11(6):543-54. PubMed ID: 19997956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Containing pandemic influenza with antiviral agents.
    Longini IM; Halloran ME; Nizam A; Yang Y
    Am J Epidemiol; 2004 Apr; 159(7):623-33. PubMed ID: 15033640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities.
    Risebrough NA; Bowles SK; Simor AE; McGeer A; Oh PI
    J Am Geriatr Soc; 2005 Mar; 53(3):444-51. PubMed ID: 15743287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.
    Sander B; Hayden FG; Gyldmark M; Garrison LP
    Pharmacoeconomics; 2006; 24(4):373-86. PubMed ID: 16605283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective, robust design of community mitigation for pandemic influenza: a systematic examination of proposed US guidance.
    Davey VJ; Glass RJ; Min HJ; Beyeler WE; Glass LM
    PLoS One; 2008 Jul; 3(7):e2606. PubMed ID: 18596963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. School closure policies at municipality level for mitigating influenza spread: a model-based evaluation.
    Ciavarella C; Fumanelli L; Merler S; Cattuto C; Ajelli M
    BMC Infect Dis; 2016 Oct; 16(1):576. PubMed ID: 27756233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the economic impact of pandemic influenza: An application of the computable general equilibrium model to the U.K.
    Smith RD; Keogh-Brown MR; Barnett T
    Soc Sci Med; 2011 Jul; 73(2):235-44. PubMed ID: 21708419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the impact of the next influenza pandemic using household-based public health interventions.
    Wu JT; Riley S; Leung GM
    Hong Kong Med J; 2009 Dec; 15 Suppl 9():38-41. PubMed ID: 20393225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit of stockpiling drugs for influenza pandemic.
    Balicer RD; Huerta M; Davidovitch N; Grotto I
    Emerg Infect Dis; 2005 Aug; 11(8):1280-2. PubMed ID: 16102319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling targeted layered containment of an influenza pandemic in the United States.
    Halloran ME; Ferguson NM; Eubank S; Longini IM; Cummings DA; Lewis B; Xu S; Fraser C; Vullikanti A; Germann TC; Wagener D; Beckman R; Kadau K; Barrett C; Macken CA; Burke DS; Cooley P
    Proc Natl Acad Sci U S A; 2008 Mar; 105(12):4639-44. PubMed ID: 18332436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.